Hemispherx Biopharma Announces Phase 3 Chronic Fatigue Syndrome Trial Meets Pri
- Hemispherx Biopharma Announces Phase 3 Chronic Fatigue Syndrome Trial Meets Primary Endpoint
Monday May 3, 8:02 am ET
Patients Receiving Ampligen Improve at Twice the Level Considered Medically Significant
TUCSON, Ariz.--(BUSINESS WIRE)--May 3, 2004-- Hemispherx Biopharma, Inc. (AMEX: HEB - News) announced today that its pivotal Phase III Chronic Fatigue Syndrome (CFS) trial of Ampligen met its primary endpoint with patients receiving Ampligen for 40 weeks. A statistically significant increase (p=0.022) in patients' physical performance as measured by Treadmill Exercise Tolerance Testing (ETT) was found, compared to placebo. Ampligen represents one of a new class of drugs called dsRNA drugs for the potential treatment of CFS that afflict more than 500,000 people in the United States. Following peer review, the Ampligen study will be presented today at the 17th International Conference on Antiviral Research, held in Tucson, Arizona, in Oral Session II.
[Non-text portions of this message have been removed]